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Background and purpose: Mitoxantrone (MTX) has been shown to reduce progression of
disability and number of clinical exacerbations in patients with progressive multiple
sclerosis (MS). Prolonged administration of MTX, however, is limited by the risk of cardi-
otoxicity. Cardiac monitoring in MTX-treated patients includes usually measurement of left
ventricular ejection fraction (LVEF) by means of echocardiography. The N-terminal pro-brain
natriuretic peptide (NT-proBNP) represents a novel diagnostic tool in the assessment of
heart failure. This study was aimed to evaluate the usefulness of NT-proBNP for early
detection of MTX-induced cardiotoxicity in MS patients.
Materials and methods: We measured the NT-proBNP plasma levels in 45 MS patients who
completed 24-month MTX therapy and in 37 MS patients of control group.
Results: The median NT-proBNP plasma value was 15.12 pg/mL. In 12 MTX-treated patients
(27%), NT-proBNP plasma values were elevated, though this subgroup of patients neither
clinical showed evidence of myocardial damage nor had the LVEF value <50%. In ﬁve
patients with normal NT-proBNP, we observed LVEF decline >10%. We did not observe
correlations between the NT-proBNP levels and patient age, MS duration, relapses index,
Extended Disability Status Scale (EDSS), MTX single dose and the total cumulative dose of
MTX. In 8 patients (22%) from control group, NT-proBNP plasma levels were also elevated.
Conclusions: The results of our study conﬁrm that MTX therapy is safe for carefully selected
and closely monitored MS patients. We believe that serial evaluation of NT-proBNP levels
(before, during and after MTX therapy) can identify MS patients at high risk for MTX-induced
cardiotoxicity.
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Mitoxantrone (MTX) has been shown to reduce progression of
disability and clinical exacerbations in patients with progres-
sive multiple sclerosis (MS) [1]. Mitoxantrone is approved by
the European Medicines Agency (EMEA) and Food and Drug
Administration (FDA) for the treatment of patients with
worsening relapsing-remitting MS (RRMS), progressive-relaps-
ing MS (PRMS) and secondary progressive MS (SPMS). Although
MTX is generally well tolerated, it is associated with a variety
of potential toxic effects. One of the more serious adverse
events associated with MTX treatment is cardiotoxicity [2–4].
Cardiac monitoring in MTX-treated patients includes usually
the evaluation of left ventricular ejection fraction (LVEF) by
means of echocardiography. This technique, however, did not
exhibit the expected sensitivity for detection of early cardiac
dysfunction.
Natriuretic peptides have recently emerged as biomarkers
potentially useful in the diagnosis and prognosis stratiﬁcation
of patients with heart diseases [5,6]. The evaluation of N-
terminal pro-brain natriuretic peptide (NT-proBNP) provides
information independent from the traditional diagnostic
measures [7]. NT-proBNP was found to be an independent
predictor of mortality or cardiac events [8,9]. Some studies
showed that in patients after high-dose chemotherapy
persistently increased NT-proBNP is strongly associated with
development of cardiac dysfunction [10]. These ﬁndings have
important practical implications for identifying patients at risk
of developing MTX-induced cardiotoxicity.
2. Materials and methods
We examined 82 patients with clinically deﬁned MS, according
to the McDonald criteria, revision 2010 [11]. Examined patients
were divided into two groups, A and B: the group A consisted of
45 patients who completed 24 months of MTX therapy, and the
group B consisted of 37 MS patients who were not treated with
MTX (Table 1). There were 24 females and 21 males in group A;
their mean age was 43  9 years, mean disease duration was
16  9 years, and mean Expanded Disability Status ScaleTable 1 – Characteristics of patients in groups A and B.
Group A
(patients
after MTX therapy)
Group B
(control group)
Number of patients 45 37
Age [years]; mean  SD 43  9 37  11
MS duration
[years]; mean  SD
16  9 11  8
EDSS score; mean  SD 3.6  1.8 3.6  1.7
Patients with RRMS (n) 17 25
Patients with PRMS (n) 16 7
Patients with SPMS (n) 12 5
MTX, mitoxantrone; MS, multiple sclerosis; SD, standard deviation;
EDSS, Expanded Disability Status Scale; RRMS, relapsing-remitting MS;
PRMS, progressive-relapsing MS; SPMS, secondary progressive MS.(EDSS) score was 3.6  1.8. In 17 patients, MS course was
relapsing-remitting (RRMS), in 16 – progressive-relapsing
(PRMS) and in 12 patients – secondary progressive (SPMS).
The total cumulative dose of MTX was 86.8  20.6 mg/m2.
Mitoxantrone was administered every 3 months with mean
MTX single dose of 9.2  1.8 mg/m2. In group B, there were 25
females and 12 males, their mean age was 37  11 years, mean
disease duration was 11  8 years, and mean EDSS was 3.6
 1.7. Relapsing-remitting MS was diagnosed in 25 patients,
PRMS – in 7 patients and SPMS – in 5 patients. Eleven patients
previously underwent therapy with interferon beta-1b and
three with glatiramer acetate.
All patients underwent extensive neurologic evaluation;
impairment and disability were measured using EDSS.
In all patients, we evaluated basic laboratory tests during
MTX treatment and follow-up phase. Troponin serum con-
centration was measured in all patients.
2.1. NT-proBNP evaluation
Blood samples were taken after 24 months of MTX treatment.
They were collected into tubes containing sodium citrate
solution. The samples were then centrifuged and plasma was
stored at 70 8C until analysis was performed. NT-proBNP
plasma concentration was measured using immunoassay
based on double-antibody sandwich technique (Biomedica).
As the cutoff, we used the value approved by FDA: <125 pg/mL.
2.2. Echocardiographic analyses
All patients underwent cardiologic evaluation including
transthoracic echocardiography. Clinical examination was
performed at each visit in order to exclude the presence of
overt heart disease. Serial transthoracic two-dimensional
echocardiograms were obtained from each patient before
starting therapy for MS, 12 months after the treatment
initiation and after the end of treatment. All examinations
were performed by an experienced sonographer with the
patient in left lateral decubitus position using Hewlett-Packard
Sonos 2500 (Hewlett-Packard, Andover, USA) and Philips iE33
(Philips, Eindhoven, Netherlands). Left ventricle end-systolic
and end-diastolic volumes as well as the ejection fraction were
calculated on the basis of the biplane Simpson's rule.
2.3. Statistical analysis
Patient characteristics by type of NT-proBNP response pattern
were compared by the Fisher exact test for categorical
variables and Wilcoxon two-sample test for continuous
variables. All analyses were conducted with SAS [12]. A two-
sided P-value < 0.05 was considered statistically signiﬁcant.
3. Results
The median NT-proBNP plasma level in group A (after MTX
treatment) was 15.12 pg/mL (range: 0–739.2 pg/mL, mean 85.1
 157.5 pg/mL). NT-proBNP plasma concentration was in-
creased in 12 patients (7 females and 5 males, 27% of examined
patients). In group of patients with elevated NT-proBNP
Table 2 – The N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma concentrations in patients treated with
mitoxantrone.
Variables NT-proBNP > 125 pg/mL NT-proBNP < 125 pg/mL
NT-proBNP [pg/mL]; mean  SD 291.6  188.0 10.2  15.9
Number of patients 12 33
Age [years]; mean  SD 39.5  9.9 44.1  8.7
MS duration [years]; mean  SD (years) 14.7  7.5 16.5  9.8
EDSS score before treatment; mean  SD 4.5  1.5 4.3  1.6
EDSS score after the end of treatment; mean  SD 3.9  2.0 3.5  1.8
Number of relapses in 2 years before treatment; mean  SD 3.8  3.4 3.6  3.8
Number of relapses during treatment; mean  SD 1.7  2.1 1.2  1.8
MTX – single dose [mg/m2]; mean  SD 9.1  1.4 9.3  1.8
MTX – total cumulative dose [mg/m2]; mean  SD 84.0  20.4 87.9  21.0
MTX, mitoxantrone; MS, multiple sclerosis; SD, standard deviation; EDSS, Expanded Disability Status Scale.
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249.5 pg/mL (range: 125.8–739.2 pg/mL, mean 291.1
 188.0 pg/mL). All of them neither showed clinical evidence
of myocardial damage nor had the LVEF value < 50%. Table 2
shows the characteristics of patients (group A) with normal
and increased NT-proBNP plasma concentration.
In group A, no correlation was observed between the NT-
proBNP levels and the following parameters: patients age,
MS duration, relapses number during two years before
treatment, relapses number during MTX treatment, EDSS
before treatment, EDSS after the end of treatment, MS
course: RRMS, PRMS, or SPMS, total cumulative dose of MTX
and MTX single dose. In cardiologic evaluation, none of
these patients showed clinical evidence of cardiac dysfunc-
tion. None of patients experienced reduction in LVEF to
<50% in echocardiography. Mean LVEF was 60  2%. The
LVEF decrease of more than 10% of the baseline value was
found in ﬁve patients (11.1%) but the mean LVEF remained
within normal limits (64.8  5%). The NT-proBNP plasma
level in these patients was normal.
In group B (not treated with mitoxantrone), the median NT-
proBNP plasma level was 3.4 pg/mL (range: 0–588 pg/mL, mean
85.9  155.8 pg/mL). NT-proBNP plasma concentration was
elevated in 8 patients (4 females and 4 males, 22% of examined
patients). In the group with elevated NT-proBNP concentra-
tion, the median NT-proBNP plasma value was 357 pg/mL
(range: 132.7–588 pg/mL, mean 352  137.8 pg/mL). Table 3
shows the characteristics of patients (group B) with normal
and increased NT-proBNP plasma concentration. We did not
observe clinical evidence of myocardial damage in patientsTable 3 – The N-terminal pro-brain natriuretic peptide
(NT-proBNP) plasma concentrations in the control group.
Variables NT-proBNP
> 125 pg/mL
NT-proBNP
< 125 pg/mL
Number of patients 8 29
Age [years]; mean  SD 35.2  15.1 38.2  10.0
MS duration [years]; mean  SD 11.7  13.2 10.1  5.7
EDSS score; mean  SD 3.2  1.1 3.7  1.8
MS, multiple sclerosis; SD, standard deviation; EDSS, Expanded
Disability Status Scale.with increased NT-proBNP plasma level. Left ventricular
ejection fraction below 50% (47%) was found in one patient
with normal NT-proBNP plasma concentration. This patient
had benign relapsing-remitting MS, and he did not undergo
any disease modifying therapy. In this group, as for group A,
there was no correlation between the NT-proBNP levels and
the following parameters: patients age, MS duration, EDSS, and
MS course: RRMS, PRMS, SPMS.
Elevated NT-proBNP plasma concentration was found both
in group A – treated with MTX (12 patients, 27%) and in group B
– control group (8 patients, 22%). No difference was found
between the NT-proBNP levels in both groups (P = 0.794;
Wilcoxon two-sample test; P = 0.6176; Fisher exact test).
Troponin serum concentration was normal in all patients.
4. Discussion
Treatment of MS patients with MTX requires careful monitor-
ing for its possible cardiac toxicity. Although currently
available noninvasive diagnostic techniques such as echocar-
diography may reveal cardiac dysfunction before it becomes
clinically overt, they lack adequate sensitivity to detect early
cardiac damage and to identify individuals at increased risk of
subsequent heart failure. However, there is the need to ﬁnd
easy, sensitive, moderate-cost methods, such as serum tests,
to predict MTX-induced cardiotoxicity. NT-proBNP has been
demonstrated to be a useful marker of left ventricular damage
in both symptomatic and asymptomatic patients [5,6,8].
Elevated NT-proBNP plasma levels have been found not only
in patients with acute myocardial infarction or advanced
congestive heart failure but also in patients with asymptom-
atic or minimally symptomatic left ventricular dysfunction [9].
Several studies have suggested that the assessment of NT-
proBNP plasma concentration might be useful in the detection
of clinical or subclinical left ventricular dysfunction in patients
receiving chemotherapy (anthracyclines) [10,13,14]. Horacek
et al. [13] examined 26 patients treated for acute leukemia with
2–6 cycles of chemotherapy containing anthracyclines. Mea-
surement of NT-proBNP concentration and echocardiography
were made before chemotherapy, after the ﬁrst and last cycles
and 6 months after treatment. Marked NT-proBNP elevation
correlated with left ventricle dysfunction on echocardiogra-
phy. In the study of 2005 [10], NT-proBNP level was measured
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high-dose chemotherapy. Blood samples were taken before
treatment and 12, 24, 36 and 72 h after the end of each course
of chemotherapy. Cardiac function was assessed by echocar-
diography at baseline and at 4 and 12 months after the end of
treatment. Persistently increased concentration of NT-
proBNP was associated with the development of subsequent
cardiac dysfunction. One published report showed that high
NT-proBNP level in MS patients treated with MTX preceded
echocardiographic and clinical signs of congestive heart
failure. Bertora et al. [15] evaluated ﬁve SPMS patients treated
with mitoxantrone. NT-proBNP was checked at baseline and
at each MTX administration. Echocardiography was per-
formed before treatment as well as before the fourth and
eighth MTX treatment. In one patient, increased NT-proBNP
was followed by LVEF decrease to 30%. The limitation of this
study was small sample (5 patients) and lack of control group.
Luchowski et al. [16] measured brain natriuretic peptide (BNP)
concentration in 22 MS patients during MTX treatment (at
baseline, after 9 and 15 months of mitoxantrone therapy). In
that study, BNP level slightly increased during MTX treat-
ment, exceeding normal values in only one patient. In two
other cases, about threefold increase in BNP concentration
was observed with no detectable changes in echocardio-
graphic parameters. The authors suggest that these results
indicate subclinical myocardial dysfunction in mitoxantrone-
treated group.
Our study was aimed to evaluate the usefulness of NT-
proBNP for early detection of MTX-induced cardiotoxicity in
MS patients. In our group, none of the patients experienced
congestive heart failure. Mild subclinical deterioration of
cardiac function (LVEF decline of more than 10% from the
baseline value) was found in ﬁve patients (11% patients), but
still LVEF value was normal in all these patients. Elevated NT-
proBNP plasma concentrations were observed both in MS
patients treated with MTX and in MS patients who did not
undergo therapy with potentially cardiotoxic drugs. This is of
special interest, because it indicates a possibility of mild
cardiac dysfunction existing in non-treated MS patients. In
fact, signiﬁcant decrease in right and left ventricular ejection
fraction and asymptomatic ventricular dysfunction were
already shown in active MS patients without any disease
modifying therapy [17]. This may be related to the impairment
of cardiovascular autonomic function or may result from
immunological myocarditis. The possibility of cardiac dys-
function in MS makes very careful selection of patients for
MTX treatment necessary. It seems that NT-proBNP is a good
candidate for an early marker predictive of cardiac dysfunction
before and during MTX therapy in MS patients. It seams that
the normal values of LVEF and NT-proBNP should rule out the
possibility of heart failure during MTX therapy. On the
contrary, the increased NT-proBNP level can indicate patients
at risk of cardiac disorders. These patients need thorough and
frequent echocardiographic evaluation.
The main limitation of our study was that the NT-proBNP
plasma concentration was measured only once after the end of
MTX treatment. We believe that serial evaluation of NT-
proBNP levels (before, during and after MTX therapy) could
signiﬁcantly increase the detection of early cardiac dysfunc-
tion in such patients.5. Conclusions
Mitoxantrone therapy is safe for carefully selected and closely
monitored MS patients. Whether or not the elevated NT-
proBNP level can identify MS patients at highest risk for MTX-
induced cardiotoxicity requires further study.
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